Zobrazeno 1 - 10
of 1 039
pro vyhledávání: '"Harousseau Jl"'
Autor:
Noel Milpied, Aline Clavert, Philippe Moreau, Steven Le Gouill, Béatrice Mahé, Thierry Guillaume, Harousseau Jl, Eolia Brissot, Florent Malard, Thomas Gastinne, Jacques Delaunay, Patrice Chevallier, Viviane Dubruille, Zinaida Peric, Nicolas Blin, Mohamad Mohty
Publikováno v:
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, 2016, 23 (1), pp.140-146. ⟨10.1016/j.bbmt.2016.10.011⟩
Biology of Blood and Marrow Transplantation, Elsevier, 2016, 23 (1), pp.140-146. ⟨10.1016/j.bbmt.2016.10.011⟩
Biology of Blood and Marrow Transplantation, 2016, 23 (1), pp.140-146. ⟨10.1016/j.bbmt.2016.10.011⟩
Biology of Blood and Marrow Transplantation, Elsevier, 2016, 23 (1), pp.140-146. ⟨10.1016/j.bbmt.2016.10.011⟩
International audience; Late complications (LC) and quality of life (QOL) were analyzed in 110 adult patients who underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) and were alive for more than 2 years afte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::194c994354fedff257c29cead0c25cd5
https://www.hal.inserm.fr/inserm-01419231
https://www.hal.inserm.fr/inserm-01419231
Autor:
Sylvie Hermouet, Harousseau Jl, Marjorie Boissinot, J.-P. Issa, Ponge T, Jaroslav Jelinek, Cédric Cleyrat, François Girodon
Publikováno v:
Leukemia. 24:1069-1073
JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5
Autor:
Harousseau Jl
Publikováno v:
Bone Marrow Transplantation. 40:1123-1128
The place of allogeneic SCT in the management of multiple myeloma remains controversial. Although it may induce long-term clinical and molecular remissions, the very high transplant-related toxicity after a myeloablative preparative regimen has limit
Autor:
Kumar S. K., Lee J. H., Lahuerta J. J., Morgan G., Richardson P. G., Crowley J., Haessler J., Feather J., Hoering A., Moreau P., LeLeu X., Hulin C., Klein S. K., Sonneveld P., Siegel D., Bladé J., Goldschmidt H., Jagannath S., Miguel J. S., Orlowski R., Palumbo A., Sezer O., Rajkumar S. V., Durie B. G. International Myeloma Working Group Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben Yehuda D, Bensinger B, Bergsagel PL, Bird J, Bladé J, Boccadoro M, Chanan Khan A, Chen WM, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen HE, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, LeLeu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nahi H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Rajkumar SV, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, San Miguel J, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Vande Broek I, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J., CAVO, MICHELE
Publikováno v:
Kumar, S K, Lee, J H, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, Leleu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V, Durie, B G M, Abildgaard, N, Abonour, R, Alexanian, R, Alsina, M, Anderson, K C, Attal, M, Avet-Loiseau, H, Badros, A, Baris, D, Barlogie, B, Bataille, R, Beksaç, M, Belch, A, Ben-Yehuda, D, Bensinger, B, Leif Bergsagel, P, Bird, J, Bladé, J, Boccadoro, M, Cavo, M, Chanan-Khan, A, Ming Chen, W, Child, T, Chim, J, Chng, W-J, Johnsen, H & on behalf of the International Myeloma Working Group 2012, ' Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib : A multicenter international myeloma working group study ', Leukemia, vol. 26, no. 1, pp. 149-57 . https://doi.org/10.1038/leu.2011.196
Kumar, S K, Lee, JH, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V, Durie, B G M, International Myeloma Working Group & Abildgaard, N 2012, ' Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib : a multicenter international myeloma working group study ', Leukemia, vol. 26, no. 1, pp. 149-57 . https://doi.org/10.1038/leu.2011.196
Leukemia, 26(1), 149-157. Nature Publishing Group
Kumar, S K, Lee, JH, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V, Durie, B G M, International Myeloma Working Group & Abildgaard, N 2012, ' Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib : a multicenter international myeloma working group study ', Leukemia, vol. 26, no. 1, pp. 149-57 . https://doi.org/10.1038/leu.2011.196
Leukemia, 26(1), 149-157. Nature Publishing Group
Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current er
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2dbe6ffe8c2635e6295f17f425b101c
https://pure.au.dk/portal/da/publications/risk-of-progression-and-survival-in-multiple-myeloma-relapsing-after-therapy-with-imids-and-bortezomib(9b065552-2900-4784-9cd2-fd53f87d51ac).html
https://pure.au.dk/portal/da/publications/risk-of-progression-and-survival-in-multiple-myeloma-relapsing-after-therapy-with-imids-and-bortezomib(9b065552-2900-4784-9cd2-fd53f87d51ac).html
Autor:
Hervé Avet-Loiseau, Régis Bataille, Florence Magrangeas, Harousseau Jl, Samuel Granjeaud, Stephane Minvielle, Olivier Decaux, Béatrice Loriod, Daniel Birnbaum, Catherine Nguyen, Rémi Houlgatte, Valéry Nasser, François Bertucci
Publikováno v:
Blood
Blood, 2003, 101 (12), pp.4998-5006. ⟨10.1182/blood-2002-11-3385⟩
Blood, American Society of Hematology, 2003, 101 (12), pp.4998-5006. ⟨10.1182/blood-2002-11-3385⟩
Blood, 2003, 101 (12), pp.4998-5006. ⟨10.1182/blood-2002-11-3385⟩
Blood, American Society of Hematology, 2003, 101 (12), pp.4998-5006. ⟨10.1182/blood-2002-11-3385⟩
Although multiple myeloma (MM) is a unique entity, a marked heterogeneity is actually observed among the patients, which has been first related to immunoglobulin (Ig) types and light chain subtypes and more recently to chromosomal abnormalities. To f
Autor:
Harousseau Jl, Michel Attal
Publikováno v:
The Hematology Journal. 4:163-170
Autor:
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, Moiraghi B, Perez M, Greil R, Valent P, Bosly A, Martiat P, Noens L, André M, Verhoef G, Conchon M, Souza C, Nonino A, Hungria V, Zanichelli MA, Colturato V, Forrest D, Lipton JH, Savoie ML, Delage R, Lalancette M, Quintero G, Gomez M, Klamova H, Faber E, Bjerrum OW, Fredriksen H, Vestergaard H, Marcher C, Kamel H, Elzawam H, Porkka K, Remes K, Reiffers J, Guilhot F, Facon T, Tulliez M, Guerci Bresler AP, Nicolini FE, Charbonnier A, Rea D, Johnson Ansah A, Legros L, Harousseau JL, Rigal Huguet F, Escoffre M, Gardembas M, Guyotat D, Cahn JY, Gattermann N, Ottmann O, Niederwieser D, Stegelmann F, Schafhausen P, Brümmendorf T, Duyster J, Blumenstengel K, Scheid C, Kneba M, Kwong YL, Masszi T, Petrini M, Alimena G, Di Raimondo F, Rosti G, Rotoli B, Pungolino E, Amadori S, Abruzzese E, Fioritoni G, Lauria F, Bosi A, Martelli M, Rambaldi A, Ferrara F, Nobile F, Gobbi M, Carella AM, Orlandi EM, Leoni P, Tiribelli M, Levis A, Imamura M, Takahashi N, Tsukamoto N, Chiba S, Nagai T, Okamoto S, Miura O, Kurokawa M, Ohnishi K, Toba K, Nakao S, Tomita A, Miyamura K, Hino M, Maeda Y, Kimura A, Kawaguchi T, Miyazaki Y, Nakaseko C, Jinnai I, Matsuda A, Matsumura I, Ishikawa J, Ohyashiki K, Okada M, Usuki K, Kobayashi Y, Ohishi K, Imai K, Miyawaki S, Kanda Y, Park SY, Kim HJ, Sohn SK, Lee KH, Jung CW, Ong TC, Gómez Almaguer D, Kassack J, Ossenkoppele GJ, Gedde Dahl T, Hjorth Hansen H, Jedrzejczak W, Dmoszynska A, Starzak Dwozdz J, Holowiecki J, Kyrcz Krzemieñ S, Kuliczkowski K, Zaritsky A, Turkina A, Pospelova T, Goh YT, Koh LP, Demitrovicova L, Mistrik M, Ruff P, Louw V, Dreosti LM, Novitzky N, Cohen G, Cervantes F, Cañizo C, de Paz R, del Castillo S, Perez Encinas M, Sanz Alonso M, Marin F, Pérez López R, Hernandez Boluda J, Echeveste Gutierrez MA, Odriozola J, Herrera P, Steegman JL, Conde E, Lopez P, Giraldo P, Boque C, Heredia B, Font AJ, Rodriguez RF, Rodriguez MJ, Batlle J, Stenke L, Lehmann S, Wadenvik H, Simonsson B, Markevärn B, Själander A, Richter J, Bjoreman M, Eriksson KM, Chalandon Y, Shih LY, Yao M, Wang MC, Jootar S, Bunworasate U, Ulkü B, Haznedar R, Undar B, Sahin B, Marin D, Smith G, Byrne J, Holyoake T, Kalaycio M, Akard L, Heaney M, Al Janadi A, Goldberg S, Powell B, Harker WG, Shea T, Gingrich R, Glass J, Paquette R, Siegrist C, Woodson M, Fehrenbacher L, Koh H, Flinn I, Arrowsmith E, Ervin T, Guerra M, Wallach H, Berry W, Burke J, Edenfield W, Guzley G, Davis J, Richards D, Schlossman D, Kolibaba K, Alemany C, Savin M, Robbins G, Lopez J, Goldman JM, Camm J, Schiffer CA, Sargent D.J., PANE, FABRIZIO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3730::dea15626236025aa3b59ad57f14b3d2a
http://hdl.handle.net/11588/371601
http://hdl.handle.net/11588/371601
Autor:
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG, International Myeloma Working Group, TOSI, PATRIZIA, CAVO, MICHELE
Publikováno v:
Leukemia, 23(2), 215-224. Nature Publishing Group
The serum immunoglobulin-free light chain (FLC) assay measures levels of free kappa and lambda immunoglobulin light chains. There are three major indications for the FLC assay in the evaluation and management of multiple myeloma and related plasma ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ebb5931246644f68739b05d7cd7aaaa
https://hdl.handle.net/20.500.14017/fffab111-f00d-4ab4-8e6a-29742d306304
https://hdl.handle.net/20.500.14017/fffab111-f00d-4ab4-8e6a-29742d306304
Autor:
Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG, IMWG, TOSI, PATRIZIA, CAVO, MICHELE
Publikováno v:
Leukemia, 23(10), 1904-1912. Nature Publishing Group
Digital.CSIC. Repositorio Institucional del CSIC
instname
Digital.CSIC. Repositorio Institucional del CSIC
instname
Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8426ccb7dc3c7e4c87ec3e01bc233d5
https://pure.eur.nl/en/publications/8a21908f-61a6-4842-a362-4d79c88abcc7
https://pure.eur.nl/en/publications/8a21908f-61a6-4842-a362-4d79c88abcc7
Autor:
Kumar, S, Giralt, S, Stadtmauer, Ea, Harousseau, Jl, Palumbo, Antonio, Bensinger, W, Comenzo, Rl, Lentzsch, S, Munshi, N, Niesvizky, R, San Miguel, J, Ludwig, H, Bergsagel, L, Blade, J, Lonial, S, Anderson, Kc, Tosi, P, Sonneveld, P, Sezer, O, Vesole, D, Cavo, M, Einsele, H, Richardson, Pg, Durie, Bg, Rajkumar, Sv, International Myeloma Working Group
Publikováno v:
Blood, 114(9), 1729-1735. American Society of Hematology
The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31d4e2b9acf06cf934693ee79b02e3f0
https://pure.eur.nl/en/publications/c37dbdad-e9fe-4602-9985-9ff0a3ac0918
https://pure.eur.nl/en/publications/c37dbdad-e9fe-4602-9985-9ff0a3ac0918